BioDelivery Sciences Internationa.../ US09060J1060 /
22/03/2022 00:00:00 | Chg. - | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
5.5900USD | - | 2.11 mill. Turnover: - |
-Bid Size: - | -Ask Size: - | 5.6000 | 5.5900 |
GlobeNewswire
05/03
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire
15/02/2022
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: BioDelivery...
GlobeNewswire
14/02/2022
BIODELIVERY SCIENCES ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of BDSI and Encourages I...
GlobeNewswire
14/02/2022
BDSI Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of BioDelivery Sciences Internatio...
GlobeNewswire
20/01/2022
BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year Guidance
GlobeNewswire
20/12/2021
BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining Patent Exclusivity Against Alv...
GlobeNewswire
01/11/2021
Coya Therapeutics Appoints Dr. Adrian Hepner as Chief Medical Officer and Dr. Greg MacMichael as Chi...
GlobeNewswire
20/10/2021
BioDelivery Sciences to Report Third Quarter 2021 Financial Results on November 3, 2021
GlobeNewswire
05/10/2021
Journey Medical Corporation Appoints Ernest De Paolantonio as Chief Financial Officer
GlobeNewswire
09/09/2021
BioDelivery Sciences International Completes Acquisition of ELYXYB™ for Acute Migraine Treatment in ...
GlobeNewswire
07/09/2021
BioDelivery Sciences to Exhibit Three Scientific Posters Comparing BELBUCA® to Oxycodone at the PAIN...
GlobeNewswire
03/09/2021
BioDelivery Sciences to Participate in Upcoming Virtual Investor Conferences
GlobeNewswire
16/08/2021
AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors
GlobeNewswire
04/08/2021
BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved ELYXYB™...
GlobeNewswire
22/07/2021
BioDelivery Sciences to Report Second Quarter 2021 Financial Results on August 4, 2021